SpringWorks Therapeutics, Inc.

Based in the US, SpringWorks Therapeutics LLC is dedicated to developing innovative therapies for rare oncology conditions, emphasizing precision oncology and addressing significant unmet medical needs. SpringWorks Therapeutics, LLC is a biopharmaceutical company focused on treating rare oncology conditions, established in 2017 in Stamford, US. The company has raised a total of USD 75. 00 mn through funding rounds, with the most recent funding being a PIPE round of USD 224.

30 mn completed on September 12, 2019, involving investors such as Boxer Capital and Deerfield Management. CEO Saqib Islam leads the company as it continues to innovate within the oncology sector. SpringWorks Therapeutics specializes in developing innovative treatments for rare oncology conditions, focusing primarily on precision oncology. Their core product offerings include nirogacestat, a gamma secretase inhibitor evaluated in multiple combination therapy regimens for B-cell maturation-related conditions.

Additionally, the company is advancing research on mirdametinib for treating neurofibromatosis type 1 plexiform neurofibromas (NF1-PN), aiming to address significant unmet medical needs for patients with rare and aggressive cancers. In the most recent year of 2021, SpringWorks Therapeutics reported zero revenue, alongside an EBITDA of USD -172. 98 mn. The company generates revenue primarily through partnerships with academic institutions and industry collaborators, focusing on clinical trials and potential commercialization of therapeutic products, with revenue streams likely arising from licensing agreements and collaborative research with pharmaceutical companies.

SpringWorks Therapeutics plans to utilize the recent funding of USD 224. 30 mn to expand its oncology programs and advance late-stage rare disease oncology programs towards potential regulatory approval and commercialization. The company aims to launch new therapeutic products, specifically targeting expansion in the United States and Europe. With an emphasis on regulatory advancements, SpringWorks anticipates increasing its market presence and enhancing treatment options for patients suffering from rare oncological conditions.